Filing Analysis
INmune Bio Inc. entered into an amended and restated license agreement with Anthony Nolan to secure the long-term supply of umbilical cord tissue for its CORDStrom™ platform. The parent company is now a direct party to the agreement, assuming joint liability for payment obligations including a 2% royalty on net sales.
Key Facts
- The agreement was signed on April 29, 2026, amending a previous 2017 agreement between the subsidiary IMB and Anthony Nolan.
- INmune Bio Inc. (the parent) is now a party to the agreement and jointly liable for royalty payments.
- The royalty is set at 2% of net sales of products, capped at an annual maximum of £5,000,000.
- Service fees for umbilical cord tissue are £400 plus VAT, with annual CPI-linked increases starting January 1, 2027.
- The agreement term extends to 10 years from the date of the first commercial sale.
- The company can terminate the agreement with 30 days' notice, while Anthony Nolan requires 6 months' notice.
Inmune Bio, Inc. has furnished an updated investor presentation slide deck to be used in upcoming presentations. The filing is a standard Regulation FD disclosure and does not report any material changes to the company's operations or financial status.
Key Facts
- The company filed the 8-K on February 27, 2026.
- The filing includes Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the new Investor Presentation.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
INmune Bio announced it will host a webinar on February 27, 2026, to discuss the registrational pathway for its drug candidate XPro1595 (XPro™) in the treatment of early Alzheimer’s disease.
Key Facts
- The webinar is scheduled for February 27, 2026, at 9:30 a.m. ET.
- The presentation will focus on the registrational pathway for XPro1595.
- The target indication for the drug candidate is early Alzheimer’s disease.
- The announcement was made via a press release attached as Exhibit 99.1.
Inmune Bio, Inc. filed an 8-K under Item 8.01 (Other Events) to announce a webinar on its CORDStrom therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), scheduled for February 26, 2026. This is a routine informational filing with no material financial or corporate governance implications.
Key Facts
- Company will host a webinar on CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET
- Filing signed by CEO David Moss on February 19, 2026
- Company is listed on NASDAQ under ticker INMB, common stock par value $0.001 per share
- Company is incorporated in Nevada with principal offices in Boca Raton, Florida
- Company is NOT classified as an emerging growth company
- Press release attached as Exhibit 99.1